Novartis AG
NVS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $11,939,000 | $8,572,000 | $6,049,000 | $22,905,000 |
| Dep. & Amort. | $6,069,000 | $8,277,000 | $6,705,000 | $5,597,000 |
| Deferred Tax | $1,701,000 | $551,000 | $1,128,000 | $1,625,000 |
| Stock-Based Comp. | $1,044,000 | $865,000 | $791,000 | $700,000 |
| Change in WC | -$706,000 | -$369,000 | -$796,000 | -$73,000 |
| Other Non-Cash | -$2,428,000 | -$3,438,000 | $359,000 | -$15,683,000 |
| Operating Cash Flow | $17,619,000 | $14,458,000 | $14,236,000 | $15,071,000 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$1,366,000 | -$1,060,000 | -$916,000 | -$1,066,000 |
| Net Acquisitions | -$3,825,000 | -$3,569,000 | -$864,000 | $20,464,000 |
| Inv. Purchases | -$3,648,000 | -$747,000 | -$34,810,000 | -$16,591,000 |
| Inv. Sales/Matur. | $3,701,000 | $11,596,000 | $39,490,000 | $2,738,000 |
| Other Inv. Act. | -$2,375,000 | -$624,000 | -$1,432,000 | -$1,337,000 |
| Investing Cash Flow | -$7,513,000 | $5,596,000 | $1,468,000 | $4,208,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $4,390,000 | -$1,935,000 | -$2,585,000 | -$5,670,000 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | -$8,331,000 | -$8,719,000 | -$10,652,000 | -$3,057,000 |
| Dividends Paid | -$7,624,000 | -$7,255,000 | -$7,506,000 | -$7,368,000 |
| Other Fin. Act. | -$177,000 | $3,631,000 | $181,000 | -$169,000 |
| Financing Cash Flow | -$11,742,000 | -$14,278,000 | -$20,562,000 | -$16,264,000 |
| Forex Effect | -$298,000 | $100,000 | -$32,000 | -$266,000 |
| Net Chg. in Cash | -$1,934,000 | $5,876,000 | -$4,890,000 | $2,749,000 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $13,393,000 | $7,517,000 | $12,407,000 | $9,658,000 |
| End Cash | $11,459,000 | $13,393,000 | $7,517,000 | $12,407,000 |
| Free Cash Flow | $13,805,000 | $11,705,000 | $11,997,000 | $12,515,000 |